{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '11.4.', 'Appendix 4: Contraceptive Guidance and Collection of', 'Pregnancy Information', '11.4.1.', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause.', 'A high follicle stimulating hormone (FSH) level in the postmenopausal', 'range may be used to confirm a postmenopausal state in women not', 'using hormonal contraception or hormonal replacement therapy (HRT).', 'However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they', 'wish to continue their HRT during the study. Otherwise, they must', 'discontinue HRT to allow confirmation of postmenopausal status before', 'study enrollment.', '11.4.2.', 'Contraception Guidance', 'Female participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 3.', 'The list does not apply to FRP with same sex partners or for participants who are and will', 'continue to be abstinent from penile-vaginal intercourse on a long term and persistent', '98']['2017N331008_00', 'CONFIDENTIAL', '208090', 'basis, when this is their preferred and usual lifestyle. Periodic abstinence (e.g. calendar,', 'ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable', 'methods of contraception.', 'Table 3', 'List of Highly Effective Contraceptive Methods', 'CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:', 'Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when', 'used consistently and correctly.', 'Implantable progestogen-only hormone contraception associated with inhibition of ovulation', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'Bilateral tubal occlusion', 'Vasectomized partner', 'Note: Vasectomized partner is a highly effective contraceptive method provided that the', 'partner is the sole sexual partner of the woman of childbearing potential and the absence', 'of sperm has been confirmed. If not, an additional highly effective method of', 'contraception should be used. Spermatogenesis cycle is approximately 90 days.', 'Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used', 'consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulation', 'oral', 'intravaginal', 'transdermal', 'injectable', 'Progestogen-only hormone contraception associated with inhibition of ovulation', 'oral', 'injectable', 'Sexual abstinence', 'Note: Sexual abstinence is considered a highly effective method only if defined as', 'refraining from heterosexual intercourse during the entire period of risk associated with', 'the study intervention. The reliability of sexual abstinence needs to be evaluated in', 'relation to the duration of the study and the preferred and usual lifestyle of the participant', 'a.', 'Contraceptive use by men or women should be consistent with local regulations regarding the use of', 'contraceptive methods for those participating in clinical studies.', 'b.', 'Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those when', 'used consistently and correctly.', '99']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Note: Periodic abstinence (calendar, sympto-thermal, post-ovulation methods), withdrawal (coitus interruptus),', 'spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Male', 'condom and female condom should not be used together (due to risk of failure with friction)', 'These allowed methods of contraception are only effective when used consistently,', 'correctly and in accordance with the product label. The investigator is responsible for', 'ensuring that participants understand how to properly use these methods of contraception.', '11.4.3.', 'Collection of Pregnancy Information', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to', \"ViiV/GSK/PPD within 2 weeks of learning of a participant's pregnancy.\", 'Participants will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to ViiV/GSK/PPD. Generally, follow-up will not be required for longer', \"than 6 to 8 weeks beyond the estimated delivery date. GSK's central safety\", 'department will forward this information to the Antiretroviral Pregnancy Registry.', 'The international registry is jointly sponsored by manufacturers and licensees of', 'antiretroviral products. Additional information and a list of participating', 'manufacturers/licensees are available from http://www.apregistry.com/.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy for medical reasons will be', 'reported as an AE or SAE.', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs and must be reported.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study intervention by the investigator, will be reported to', 'ViiV/GSK/PPD as described in Appendix 8. While the investigator is not obligated', 'to actively seek this information in former study participants, he or she may learn of', 'an SAE through spontaneous reporting.', 'Any female participant who becomes pregnant while participating will be withdrawn', 'from the study.', '100']\n\n###\n\n", "completion": "END"}